Cargando…

The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg

Childhood absence epilepsy (CAE) is a non-convulsive seizure disorder primarily in children characterized by absence seizures. Absence seizures consist of 2.5–5 Hz spike-and-wave discharges (SWDs) detectable using electroencephalography (EEG). Current drug treatments are only partially effective and...

Descripción completa

Detalles Bibliográficos
Autores principales: McElroy, Dan L., Roebuck, Andrew J., Greba, Quentin, Garai, Sumanta, Brandt, Asher L., Yilmaz, Orhan, Cain, Stuart M., Snutch, Terrance P., Thakur, Ganesh A., Laprairie, Robert B., Howland, John G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804275/
https://www.ncbi.nlm.nih.gov/pubmed/35128516
http://dx.doi.org/10.1016/j.ibneur.2022.01.006
_version_ 1784643040850214912
author McElroy, Dan L.
Roebuck, Andrew J.
Greba, Quentin
Garai, Sumanta
Brandt, Asher L.
Yilmaz, Orhan
Cain, Stuart M.
Snutch, Terrance P.
Thakur, Ganesh A.
Laprairie, Robert B.
Howland, John G.
author_facet McElroy, Dan L.
Roebuck, Andrew J.
Greba, Quentin
Garai, Sumanta
Brandt, Asher L.
Yilmaz, Orhan
Cain, Stuart M.
Snutch, Terrance P.
Thakur, Ganesh A.
Laprairie, Robert B.
Howland, John G.
author_sort McElroy, Dan L.
collection PubMed
description Childhood absence epilepsy (CAE) is a non-convulsive seizure disorder primarily in children characterized by absence seizures. Absence seizures consist of 2.5–5 Hz spike-and-wave discharges (SWDs) detectable using electroencephalography (EEG). Current drug treatments are only partially effective and adverse side effects have spurred research into alternative treatment approaches. Recent research shows that positive allosteric modulation of the type-1 cannabinoid receptor (CB1R) reduces the frequency and duration of SWDs in Genetic Absence Epilepsy Rats from Strasbourg (GAERS), a model that recapitulates the SWDs in CAE. Here, we tested additional CB1R ago-PAMs, GAT591 and GAT593, for their potential in alleviating SWD activity in GAERS. In vitro experiments confirm that GAT591 and GAT593 exhibit increased potency and selectivity in cell cultures and behave as CB1R allosteric agonists and PAMs. To assess drug effects on SWDs, bilateral electrodes were surgically implanted in the somatosensory cortices of male GAERS and EEGs recorded for 4 h following systemic administration of GAT591 or GAT593 (1.0, 3.0 and 10.0 mg/kg). Both GAT591 and GAT593 dose-dependently reduced total SWD duration during the recording period. The greatest effect on SWD activity was observed at 10.0 mg/kg doses, with GAT591 and GAT593 reducing seizure duration by 36% and 34% respectively. Taken together, these results support the continued investigation of CB1R PAMs as a potential therapeutic to alleviate SWDs in absence epilepsy.
format Online
Article
Text
id pubmed-8804275
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88042752022-02-04 The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg McElroy, Dan L. Roebuck, Andrew J. Greba, Quentin Garai, Sumanta Brandt, Asher L. Yilmaz, Orhan Cain, Stuart M. Snutch, Terrance P. Thakur, Ganesh A. Laprairie, Robert B. Howland, John G. IBRO Neurosci Rep Article Childhood absence epilepsy (CAE) is a non-convulsive seizure disorder primarily in children characterized by absence seizures. Absence seizures consist of 2.5–5 Hz spike-and-wave discharges (SWDs) detectable using electroencephalography (EEG). Current drug treatments are only partially effective and adverse side effects have spurred research into alternative treatment approaches. Recent research shows that positive allosteric modulation of the type-1 cannabinoid receptor (CB1R) reduces the frequency and duration of SWDs in Genetic Absence Epilepsy Rats from Strasbourg (GAERS), a model that recapitulates the SWDs in CAE. Here, we tested additional CB1R ago-PAMs, GAT591 and GAT593, for their potential in alleviating SWD activity in GAERS. In vitro experiments confirm that GAT591 and GAT593 exhibit increased potency and selectivity in cell cultures and behave as CB1R allosteric agonists and PAMs. To assess drug effects on SWDs, bilateral electrodes were surgically implanted in the somatosensory cortices of male GAERS and EEGs recorded for 4 h following systemic administration of GAT591 or GAT593 (1.0, 3.0 and 10.0 mg/kg). Both GAT591 and GAT593 dose-dependently reduced total SWD duration during the recording period. The greatest effect on SWD activity was observed at 10.0 mg/kg doses, with GAT591 and GAT593 reducing seizure duration by 36% and 34% respectively. Taken together, these results support the continued investigation of CB1R PAMs as a potential therapeutic to alleviate SWDs in absence epilepsy. Elsevier 2022-01-24 /pmc/articles/PMC8804275/ /pubmed/35128516 http://dx.doi.org/10.1016/j.ibneur.2022.01.006 Text en © 2022 Published by Elsevier Ltd on behalf of International Brain Research Organization. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
McElroy, Dan L.
Roebuck, Andrew J.
Greba, Quentin
Garai, Sumanta
Brandt, Asher L.
Yilmaz, Orhan
Cain, Stuart M.
Snutch, Terrance P.
Thakur, Ganesh A.
Laprairie, Robert B.
Howland, John G.
The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg
title The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg
title_full The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg
title_fullStr The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg
title_full_unstemmed The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg
title_short The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg
title_sort type 1 cannabinoid receptor positive allosteric modulators gat591 and gat593 reduce spike-and-wave discharges in genetic absence epilepsy rats from strasbourg
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804275/
https://www.ncbi.nlm.nih.gov/pubmed/35128516
http://dx.doi.org/10.1016/j.ibneur.2022.01.006
work_keys_str_mv AT mcelroydanl thetype1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT roebuckandrewj thetype1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT grebaquentin thetype1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT garaisumanta thetype1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT brandtasherl thetype1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT yilmazorhan thetype1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT cainstuartm thetype1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT snutchterrancep thetype1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT thakurganesha thetype1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT laprairierobertb thetype1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT howlandjohng thetype1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT mcelroydanl type1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT roebuckandrewj type1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT grebaquentin type1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT garaisumanta type1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT brandtasherl type1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT yilmazorhan type1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT cainstuartm type1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT snutchterrancep type1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT thakurganesha type1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT laprairierobertb type1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg
AT howlandjohng type1cannabinoidreceptorpositiveallostericmodulatorsgat591andgat593reducespikeandwavedischargesingeneticabsenceepilepsyratsfromstrasbourg